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Metronomic chemotherapy is currently considered an emerging therapeutic option in clinical oncology.
S-1, an oral formulation of Tegafur (TF), a prodrug of 5-ﬂuorouracil (5-FU), is designed to improve the
antitumor activity of 5-FU in tandem with reducing its toxicity. Clinically, metronomic S-1 dosing has
been approved for the standard ﬁrst- and second-line treatment of metastatic or advanced stage of
colorectal (CRC). However, expression of intratumor thymidylate synthase (TS), a signiﬁcant gene in
cellular proliferation, is associated with poor outcome to 5-FU-based chemotherapeutic regimens. In this
study, therefore, we examined the effect of a combination of TS silencing by an RNA interfering molecule,
chemically synthesized short hairpin RNA against TS (shTS), and 5-FU on the growth of human colorectal
cancer cell (DLD-1) both in vitro and in vivo. The combined treatment of both shTS with 5-FU substan-
tially inhibited cell proliferation in vitro. For in vivo treatments, the combined treatment of metronomic
S-1 dosing with intravenously injected polyethylene glycol (PEG)-coated shTS-lipoplex signiﬁcantly
suppressed tumor growth, compared to a single treatment of either S-1 or PEG-coated shTS-lipoplex. In
addition, the combined treatment increased the proportion of apoptotic cells in the DLD-1 tumor tissue.
Our results suggest that metronomic S-1 dosing combined with TS silencing might represent an
emerging therapeutic strategy for the treatment of patients with advanced CRC.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Colorectal cancer (CRC) is one of the most common causes of
malignancy-related deaths in the world [1]. Although the signiﬁ-
cant progress that had been attained in the chemotherapy of CRC
over the past decade, chemotherapeutic agents have only improved
the outcome of early stage CRC but not the outcome of advanced
CRC [2]. Therefore, the introduction of novel therapeutic agents
and/or options are urged to further improve the outcome of
chemotherapy for advanced CRC.netics and Biopharmaceutics,
, Tokushima, Japan. Fax: þ81
a).
er Ireland Ltd. This is an open acce
ila, et al., Metronomic S-1 do
del, Cancer Letters (2016), htThe therapeutic concept of administering chemotherapeutic
agents continuously at lower doses, relative to the maximum
tolerated dose (MTD) without drug-free breaks over extended
periods eknown as “metronomic chemotherapy”e is a promising
approach in cancer therapy [3,4]. Fluoropyrimidines (including 5-
ﬂuorouracil, 5-FU) are considered the mainstay for CRC and other
gastrointestinal malignancies [5,6]. Recently, metronomic dosing
of S-1, an oral 5-FU formulation consisting of tegafur (FT; a
prodrug of 5-FU) [7], has been acknowledged for achieving sus-
tained 5-FU plasma concentrations, mimicking the pharmacoki-
netics of a continuous infusion of 5-FU while eliminating the
inconvenience associated with the continuous infusion of 5-FU
[8] and the rapid degradation of 5-FU into its inactive form in
the liver and tumors [2]. In addition, metronomic S-1 dosing has
shown a superior efﬁcacy than 5-FU in the treatment of advanced
or metastatic gastric cancer and CRC [9]. Nonetheless, like other
ﬂuoropyrimidine derivatives, including 5-FU, S-1 showed ass article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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remarkable antitumor effects can only be realized in the clinical
setting by combining the “metronomic therapy” with other
therapeutic agents.
Many reports have emphasized the correlation between thy-
midylate synthase (TS; a folate-dependent enzyme that plays a
crucial role in the biosynthesis of thymidylate, an essential pre-
cursor for DNA synthesis) expression level and the responsiveness
in patients with advanced CRC treated with 5-FU-based chemo-
therapy [11e13]. High expression of TS has been associated with
poor prognosis and/or disease refractory to ﬂuoropyrimidines-
based chemotherapy in several cancers including colorectal and
head and neck cancer [14].
Many small-molecular weight therapeutics were applied to
inhibit TS expression, however, treatment with such TS inhibitors
failed to induce efﬁcient down-regulation of TS expression [15].
Instead, silencing of TS by RNA interference (RNAi) may be
considered as an efﬁcient alternative approach to down-regulate TS
expression. RNAi is considered as a promising regulatory process in
which double-stranded RNA (dsRNA) induces speciﬁc degradation
of its target mRNA [16]. A growing number of studies have used
siRNAs/shRNAs as potential therapeutic agents for treating
numerous diseases, including cancer and genetic or viral infections
[17,18].
In this study, therefore, we investigated the efﬁcacy of gene
silencing using chemically synthesized short hairpin RNA targeting
TS (shTS) in suppressing the TS expression, and thereby enhancing
the cell growth inhibitory effect of 5-FU on colorectal tumor cell
line, DLD-1, in vitro. In addition, we evaluated the in vivo antitumor
efﬁcacy of a combination treatment with metronomic S-1 dosing
(p.o.) and PEG-coated shTS-lipoplex (i.v.) in a subcutaneous xeno-
graft mouse model.
Materials and methods
Materials
5-FU and S-1were generously donatedby Taiho Pharmaceutical (Tokyo, Japan).1-
palmitoyl 2-oleoyl phosphatidylcholine (POPC), dioleoylphosphatidylethanolamine
(DOPE) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-(methoxy (poly-
ethyleneglycol)-2000) (mPEG2000-DSPE) were generously donated by NOF (Tokyo,
Japan). Cholesterol (CHOL)was purchased fromWakoPure Chemical (Osaka, Japan). A
cationic lipid, O,O0-ditetradecanoyl-N-(alpha-trimethyl ammonioacetyl) diethanol-
amine chloride (DC-6-14) was purchased from Sogo Pharmaceutical (Tokyo, Japan).
Opti-MEM I and Lipofectamine RNAiMAX (Lf RNAiMAX) were purchased from Invi-
trogen (San Diego, CA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Nacalai Tesque (Kyoto, Japan). All other
reagents were of analytical grade.
Animals and tumor cell line
5-week-old male BALB/c nu/nu mice were purchased from Japan SLC (Shizuoka,
Japan). The experimental animals were allowed free access towater andmouse chow,
and were housed under controlled environmental conditions (constant temperature,
humidity, and 12-h darkelight cycle). All animal experiments were evaluated and
approved by the Animal and Ethics Review Committee of Tokushima University. A
human colon carcinoma cell line, DLD-1 was maintained in RPMI-1640 medium
(Wako Pure Chemical) supplemented with 10% heat-inactivated fetal bovine serum
(Japan Bioserum, Hiroshima, Japan), 100 units/ml penicillin, and 100 mg/ml strepto-
mycin (ICN Biomedicals, Irvine, CA, USA) in a 5% CO2/air incubator at 37 C.
Chemically synthesized shRNAs
All shRNAs, chemically synthesized and puriﬁed by high performance liquid
chromatography, were purchased from Hokkaido System Science (Sapporo,
Japan). Two shRNAs were designed; one to target thymidylate synthase (shTS)
and the other was a nonspeciﬁc (shCont, not to target any gene in human
and mouse genome). The sequence of shRNA against TS (shTS) was 50-GUAA-
CACCAUCGAUCAUGAUAGU GCUCCUGGUUGUCAUGAUCGAUGGUGUUACUU-30
and for a nonspeciﬁc shRNA (shCont) was 50-UCUUAAUCGCGUAUAAGGCUA-
GUGCUCCUGGUUGGC CUUAUACGCGAUUAAGAUU-30 . shRNAs were dissolved in
RNase free TE buffer at a ﬁnal concentration of 100 mmol/l.Please cite this article in press as: A.S. Abu Lila, et al., Metronomic S-1 do
efﬁcacy in a colorectal cancer xenograft model, Cancer Letters (2016), htIn vitro gene knockdown by shRNA transfection
DLD-1 cells were seeded at a density of 500,000 cells/dish in a 10-cm dish 24 h
before shRNA transfection. The cells were transfected with 1, 5 or 10 nM shTS or
10 nM shCont in Opti-MEM I using Lf RNAiMAX according to the manufacturer's
recommended protocol. Seventy-two hours later, gene silencing of TS was exam-
ined with Western blotting as described below. Treated cells were washed with
chilled phosphate buffered saline (37 mmol/l NaCl, 2.7 mmol/l KCl, 8.1 mmol/l
Na2HPO4, and 1.47 mmol/l KH2PO4; pH 7.4) and were lysed in an NP-40 lysis buffer
(50 mmol/l TriseHCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mmol/l
NaCl, protease inhibitor cocktail (SigmaeAldrich, St Louis, MO, USA)). The lysate
was collected into a 1.5 ml Eppendorf tube and then centrifuged at 4 C for
15 min at 15,000  g. The protein concentration in the supernatant was deter-
mined using the Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA,
USA) with bovine serum albumin (SigmaeAldrich) as a standard according to the
manufacturer's recommended instruction. Equivalent amounts of protein (20 mg)
from each cell lysate were separated on a 12% SDS-PAGE gel (ATTO Corp., Tokyo,
Japan) and transferred electrophoretically onto Hybond-ECL nitrocellulose mem-
brane (GE Healthcare, Cleveland, OH, USA). The membrane was blocked with Tris-
buffered saline containing 0.05% Tween 20 and 5% BSA for 1 h at room temperature
and then incubated overnight at 4 C with primary antibodies at appropriate
concentrations (1:500 for mouse monoclonal anti-TS antibody (AnaSpec, San Jose,
CA, USA) and 1:5000 for mouse monoclonal anti-human b-actin antibody (Bio-
Vision, Mountain View, CA, USA), respectively. b-actin was used as a loading con-
trol. After three washes with Tris-buffered saline containing 0.05% Tween 20,
membranes were incubated with horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (MP Biomedicals, Solon, OH, USA) for 1 h at room
temperature. Finally, membranes were processed for enhanced chem-
iluminescence using the ECL Plus Chemiluminescence Reagent (GE Healthcare UK,
Little Chalfont, UK), and the obtained images were analyzed using LAS-4000
EPUVmini and Multi Gauge v.3.2 (FujiFilm, Tokyo, Japan).Real time-polymerase chain reaction (RT-PCR)
RNA isolation and cDNA synthesis were performed according to the manufac-
turer's instructions. Brieﬂy, cells were seeded in 48-well plates at a density of 10,000
cells/well 24 h before shRNA transfection. The cells were transfected with 5 nM shTS
or shCont for 24 h as described above. At 72 h post-transfection, the total RNA of the
DLD-1 cells was isolated using an RNaqueous-micro kit (Ambion, Austin, TX, USA).
To conduct the reverse transcription reaction, 2 ml of RNA was converted to cDNA
with a total volume of 20 ml, including 500 nM of Oligo(dT)20, 500 mM dNTP, 1 ml of
RNase inhibitor, and 1 ml of ReverTra Ace (Toyobo, Osaka, Japan). Real-time PCR was
performed on a StepOnePlus real-time PCR system (Applied Biosystems, CA, USA)
with a FastStart TaqMan Probe Master (ROX) and Universal ProbeLibrary (Roche
Diagnostics GmbH, Manheim, Germany) according to the manufacturer's in-
structions. Brieﬂy, the PCR mixture was applied to a 96-well plate in a total volume
of 20 ml/well, including a 250 nM probe, 900 nM forward and reverse primers, 2 ml of
the generated cDNA, and 10 ml of FastStart TaqMan Probe Master (ROX). The TS
primers and a probe were from the Assay-on-Demand gene expression assay mix
(TS assay ID Hs00426591-ml, PCR product size 87 bp; Applied Biosystems). The
GAPDH primers and a probe for real-time RT-PCR were designed using ProbeFinder
software (Roche Diagnostics GmbH). The GAPDH primers and the probes were as
follows: GAPDH primers and probe (forward 50-GCTCTCTGCTCCTCCTGTTC-30 and
reverse 50-ACGACCAAATCCGTTGACTC-30 , probe #60). The ampliﬁcation conditions
were as follows: 10 min at 95 C, followed by 40 cycles of 95 C for 15 s and 60 C for
1 min. The quantity was determined from the experimental threshold cycle on a
standard curve of the data from a series of serial dilutions of the mixture of
generated cDNA. The TS mRNA level was normalized with GAPDH as an endogenous
control.Cell viability assay
To determine the cytotoxicity of single-drug treatment or combined treatment
of shTS and 5-FU, DLD-1 cells were seeded in 96-well plates at a density of 2000
cells/well 24 h before shRNA transfection. The cells were transfected with 5 nM shTS
or shCont for 24 h as described above. After transfection, the culture medium was
replaced with fresh medium containing 5-FU (0.1 mg/ml). Following different incu-
bation time intervals (24, 48, 72 or 96 h) at 37 C, the cell viability was determined by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as
described previously [19]. Brieﬂy, cells were incubated with 50 ml MTT reagent
(5 mg/ml in PBS) for 4 h at 37 C. Then, 150 ml of acid-isopropanol (0.04 N HCl in
isopropanol) was added to each well to dissolve formazan crystals. The absorbance
of each well was read at 570 nm on a microplate reader, Sunrise-R (TEKAN Japan,
Kanagawa, Japan). Results were expressed as follows: Cell viability (% of control) ¼
(A570 (treated group)/A570 (non-treated control group))  100 (%), where A570 (treated group) is
the absorbance of the untransfected or transfected cells exposed to treatment with
5-FU and A570 (control group) is the absorbance of the non-treated cells. Data shown are
representative of three independent experiments.sing and thymidylate synthase silencing have synergistic antitumor
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Cationic liposome composed of DOPE:POPC:CHOL:DC-6-14 (3:2:3:2, molar ra-
tio) was prepared as described previously [20]. The mean diameter and zeta po-
tential for the cationic liposomes were 110.5 ± 16.4 nm and 24.9 ± 1.1 mV (n ¼ 3),
respectively, as determined with a NICOMP 370 HPL submicron particle analyzer
(Particle Sizing System, CA, USA). The concentration of phospholipids was deter-
mined by colorimetric assay [21].
Preparation of PEG-coated shRNA-lipoplexes
For the preparation of shRNA/cationic liposome complex (shRNA-lipoplex),
shRNA and cationic liposome were mixed at a molar ratio of 2000/1 (lipid/siRNA,
molar ratio), and the mixture was vigorously vortexed for 10 min at room temper-
ature to form shRNA-lipoplex. The mean diameter and zeta potential of shRNA-
lipoplex were 395.2 ± 29.0 nm and 17.4 ± 1.7 mV (n ¼ 3), respectively. For in vivo
application, shRNA-lipoplex was surface-modiﬁed by polyethylene glycol (PEG)-
conjugated lipid (PEGylation) using a post-insertion technique [22]. Brieﬂy,
mPEG2000-DSPE (5 mol% of total lipid) in 9% sucrose solution was added to the
shRNA-lipoplex solution, and the mixture was gently shaken for 1 h at 37 C. The
mean diameter and zeta potential of PEG-coated shRNA-lipoplex were
406.3 ± 20.1 nm and 15.7 ± 1.5 mV (n ¼ 3), respectively. To detect the free-shRNA in
the prepared PEG-coated shRNA-lipoplex, electrophoresis was performed on 2%
agarose gel in 40 mM Triseacetate/1 mM EDTA buffer and shRNA visualization is
carried out using a UV transilluminator. No bands relating free shRNAwere detected,
indicating that virtually 100% of the shRNAwas associated with and/or encapsulated
in the PEG-coated shRNA-lipoplex under our lipoplex preparation.
In vivo tumor growth suppression by the combined treatment with PEG-coated shTS
lipoplex and metronomic S-1 dosing
5-week-old male BALB/c nu/nu mice were inoculated subcutaneously at the
ﬂank regionwith DLD-1 cells (2 106) in a volume of 100 ml PBS. At day 5 post tumor
cells inoculation, when the tumor volume reached 50e60 mm3, the animals were
randomly grouped (n¼ 6) into four groups: a control group treatedwith sucrose and
three groups treated with either PEG-coated shTS lipoplex, metronomic S-1 doing or
a combination of PEG-coated shTS lipoplex plus metronomic S-1 dosing. The tumor
volume was measured every three days using a caliper, and tumor volume was
calculated using the formula: tumor volume ¼ (length)  (width)2  0.5 [19]. The
antitumor activity was determined by evaluating the tumor growth inhibition rate
using the following formula: Tumor growth inhibition rate [TGI (%)] ¼ [1 (mean
relative tumor volume of treated group)/(mean relative tumor volume of control
group)]  100, with relative tumor volume (RTV) ¼ Final tumor volume/initial tu-
mor volume [23]. PEG-coated shRNA-lipoplexes containing shTS (80 mg/mouse)
were intravenously injected every 2 days (on day 5, 7, 9, 11, 13, 15, 17, and 19), and
metronomic S-1 (Tegafur: 6.9 mg/kg) was orally administered daily (from day 5e19).
At 48 h after the last treatment (on day 21), animals were sacriﬁced and the
presence of apoptotic cells in tumor tissue was detected with the TUNEL assay using
In Situ Cell Death Detection Kit, Texas red (Roche, Indianapolis, IN, USA) according to
themanufacturer's recommended protocol. Brieﬂy, sections of frozen samples (5 mm
thick) were ﬁxed in cold acetone and blocked with 5% BSA-PBS solution for 1 h at
4 C. Apoptotic cells in the tumor sections were then detected by incubation for
1 h at 37 C with the TUNEL reaction mixture including terminal deoxynucleotidyl
transferase (TdT). Lastly, the nuclei in the tumor sections stained with Hoechst
33342 (AnaSpec, San Jose, CA. USA). The sections were examined under a ﬂuores-
cence microscope (Axiovert 200 M; Zeiss, Oberkochen, Germany), and the numbers
of apoptotic cells in tumor tissue on each section were determined in ten different
microscopic ﬁelds using analyze software (AxioVision; Zeiss, Oberkochen,
Germany).
Statistical analysis
All values are expressed as the mean ± SD. Statistical analysis was performed
with a two-tailed unpaired Student's t-test using GraphPad InStat View software
(GraphPad Software, San Diego, CA). The level of signiﬁcance was set at P < 0.05.
Results
TS gene silencing effect of shTS in DLD-1 cells in vitro
Initial studies were conducted to determine the optimal shRNA
concentration for efﬁcient TS gene silencing. As shown in Fig. 1A,
the suppression of the expression of TS by shTS was concentration-
dependent. Cells transfected with a low shTS concentration (1 nM)
failed to induce complete suppression of TS expression. However,
higher shTS concentrations (5 nM and 10 nM) were efﬁcient in
suppressing TS protein expression in DLD-1 cells. Transfection with
a nonspeciﬁc control shRNA (shCont), even at a higherPlease cite this article in press as: A.S. Abu Lila, et al., Metronomic S-1 do
efﬁcacy in a colorectal cancer xenograft model, Cancer Letters (2016), htconcentration (10 nM), had no effect on the expression level of TS
protein. To further conﬁrm the speciﬁc gene silencing effect of shTS,
the TS gene expression at the mRNA level was also examined after
the transfection of shTS and shCont (Fig. 1B). Approximately more
than 90% reduction in TS mRNA levels were observed in cells
transfected with either 5 nM or 10 nM shTS, compared to that
transfected with 10 nM shCont, conﬁrming that the reduction
observed in TS protein levels was caused by TS mRNA degradation.
Since there was no remarkable difference in gene silencing effect
between the highest two concentrations of shRNA (5 nM and
10 nM), subsequent in vitro experiments were performed at a shTS
concentration of 5 nM.
Effect of TS silencing on chemosensitivity of DLD-1 cells to 5-FU
The TS protein is the main target molecule of 5-FU [24]. It has
been reported that the expression of TS protein is highly relatedwith
chemosensitivity of tumor cells to 5-FU [13,25]. Therefore, to reveal
whether TS gene knockdown will improve the chemosensitivity of
DLD-1 cells to 5-FU, the DLD-1 cells were transfected with either
shTS or shCont, and then treated with 5-FU (0.1 mg/ml, a minimum
toxic concentration of 5-FU) for different time intervals (24, 48, 72
and 96 h). As shown in Fig. 2, as single agents, both 5-FU and shRNA
against TS (shTS) exerted a moderate cytotoxic effect against DLD-1
cells in a time-dependent manner (cell growth inhibition (%) were
41.3 ± 3.4% and 53.5 ± 2.8%, respectively at 96 h post incubation).
Control shRNA (shCont) showed no effect on the cell viability of DLD-
1 cells at any time point examined. A combination of shCont and 5-
FU seems to have no additive effect on the cytotoxicity of 5-FU
against DLD-1 cells. On the other hand, combined treatment with
5-FU and shTS substantially decreased DLD-1 cell viability in a time-
dependent manner; with a maximal cellular growth inhibition
(72.8 ± 1.7%) at 96 h post-incubation. These results suggest that
down-regulation of TS expression sensitizes the cells to the cytotoxic
effect of 5-FU, and thereby, signiﬁcantly improves the chemo-
sensitivity of DLD-1 colorectal cancer cells to 5-FU.
In vivo tumor growth suppressive effect by the combined treatment
with shTS and S-1
Next, to examine whether combination of shTS with 5-FUmight
be an effective strategy for the treatment of colorectal cancer, the
tumor growth inhibitory effect of either metronomic S-1 dosing, an
orally prodrug of 5-FU, or shTS alone or a combined treatment of
shTS and metronomic S-1 dosing was evaluated. As shown in Fig. 3,
a signiﬁcant reduction in the tumor growth was observed in DLD-1
bearing nude mice treated with shTS alone or in combination with
metronomic S-1 dosing compared with that in control group
(Fig. 3A and B). When compared with shTS or S-1 alone, the com-
bined treatment of shTS and S-1 strongly suppressed tumor growth
in DLD-1 xenograft model; the tumor growth inhibition rate (TGI
(%)) was 55.4% which was signiﬁcantly higher than that of S-1 or
shTS-treated groups (TGI (%) were 33.5% and 33.9%, respectively).
Throughout the therapeutic experiment, no body weight loss was
observed in any of the treated groups (Fig. 3C). These results sug-
gest that combined treatment with shTS and metronomic S-1
dosing signiﬁcantly augmented the antitumor efﬁcacy of 5-FU
derived from S-1 in human colorectal tumor-bearing mice
without causing remarkable toxicity.
Apoptosis induction in tumor tissue following combined treatment
with PEG-coated shTS lipoplex and metronomic S-1 dosing
To verify whether the growth inhibition of implanted DLD-1 tu-
mors by treatment with shTS alone or in combination withsing and thymidylate synthase silencing have synergistic antitumor
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DLD-1 tumor tissue, the percent of apoptotic cells within tumor
tissues was identiﬁed by TUNEL assay following treatments (Fig. 4A
and B). The number of TUNEL-positive cells in the tumor treatedwith
the combination of shTS and S-1 was signiﬁcantly higher than those
in the tumor treated with either shTS or S-1 alone (apoptotic index
was 35.2 ± 4.7 versus 21.3 ± 2.2 and 20.1 ± 1.7, respectively) (Fig. 4B).
These results emphasize that apoptosis induced by the combined
treatment substantially contributes to the augmented antitumor
efﬁcacy of the combined treatment in DLD-1 xenograft model.Fig. 1. TS gene silencing by chemically synthesized shTS in human colorectal DLD-1 cell line.
analyses, respectively. DLD-1 cells were transfected with either 10 nM shCont or 1, 5 or 10 nM
the cells and analyzed as described in the Materials and methods section. Data represent the
transfected cells.
Please cite this article in press as: A.S. Abu Lila, et al., Metronomic S-1 do
efﬁcacy in a colorectal cancer xenograft model, Cancer Letters (2016), htDiscussion
Thymidylate synthase (TS), a signiﬁcant gene in cellular prolif-
eration, is an important target in cancer chemotherapy due to its
crucial role in DNA precursor synthesis and repair [26]. Not only is
TS a mainstay target of many currently used chemotherapeutic
agents such as the ﬂuoropyrimidine including S-1 [27] and the
antifolate drugs; raltitrexed and pemetrexed [28], but it is also the
target for developing antisense therapies [29] to enhance the
chemosensitivity to those drugs.Expression of TS protein (A) and mRNA (B) were detected by western blot and qRT-PCR
shTS using Lf RNAiMAX. At 72 h post-transfection, protein or RNAwas extracted from
mean ± S.D from three independent experiments. ***p < 0.005 compared with shCont-
sing and thymidylate synthase silencing have synergistic antitumor
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Fig. 2. Effect of combined treatment of shTS and 5-FU on the viability of DLD-1 cells in vitro. DLD-1 cells were transfected or not with 5 nM of shCont or shTS. At 24 h post-
transfection, fresh medium containing 0.1 mg/ml 5-FU was added and the cells were further incubated for different time intervals (24, 48, 72 or 69 h). After each indicated in-
cubation time, cell viability was measured by MTT assay. Data represent the mean ± S.D from three independent experiments. ***p < 0.005 versus shTS- or 5-FU-treated cells.
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sion is reported to promote tumor growth [15]. In addition, TS
mRNA and protein expression levels strongly predict the outcome
with 5-FU-based therapeutic regimens [30,31]. Thus, the down-
regulation of TS may be a promising approach to improve the
therapeutic efﬁcacy of TS targeting chemotherapeutic agents. In
this study, using the RNAi strategy with TS-targeted chemically
synthesized shRNA (shTS), we demonstrated that shTS could
effectively inhibit the growth of implanted DLD-1 cells in nude
mice (Fig. 3A and B). Such potent tumor growth inhibitory effect
was strongly related to in vitro down-regulation of TS mRNA and
protein expression (Fig. 1A and B) and induction of in vivo DLD-1
cell apoptosis (Fig. 4A and B). Interestingly, when combined with
5-FU, shTS sensitized the DLD-1 cells to the cytotoxic effect of 5-FU
in vitro (Fig. 2) and augmented the antitumor efﬁcacy of S-1, an oral
prodrug of 5-FU, in xenograft tumor model (Fig. 3A and B) via the
induction of a potent apoptotic response in DLD-1 tumors (Fig. 4A
and B). These results suggest that combination of shRNA targeting
TS and S-1 may be a promising approach in the treatment of
advanced colorectal cancer.
Effectively treating patients with advanced CRC is not an easy
task. Conventional chemotherapy given at maximal tolerated doses
(MTD) results in modest control in cancer progression [32,33].
Instead, metronomic chemotherapy, describes the close, regular
administration of chemotherapy drugs at less-toxic doses over
prolonged periods of time, has been recently emerged as an alter-
native therapeutic option to conventional chemotherapy [34,35].
Metronomic chemotherapy holds much promise to circumvent
several of the major pitfalls of MTD regimens. A lower incidence of
drug resistance, restoration of anti-tumor immunity, reduced
toxicity, better quality of life, and/or a lower ﬁnancial burden forPlease cite this article in press as: A.S. Abu Lila, et al., Metronomic S-1 do
efﬁcacy in a colorectal cancer xenograft model, Cancer Letters (2016), htpatients, collectively exalts the therapeutic potential of metro-
nomic chemotherapy compared with MTD-administered conven-
tional chemotherapies [36e38]. It is unfortunate, however, that
metronomic chemotherapy, as the sole therapeutic modality, has
exhibited dismal therapeutic efﬁcacy in many preclinical/clinical
settings. Therefore, the introduction of new therapeutic strategies
is potentially urged to further improve the therapeutic outcome of
chemotherapy for colorectal cancer. Our strategy using RNAi would
be an emerging therapeutic option to achieve good therapeutic
outcome with metronomic 5-FU-based treapeutics in patients with
advanced CRC.
RNAi technology has been developed as a potential therapeutic
strategy for several diseases, including cancer [39]. Many chemi-
cally synthesized RNAi molecules [siRNA, oligodeoxynucleotides
(ODNs), microRNA, and short-hairpin RNA] have emerged as agents
for treating human disease [40]. RNAi can inhibit translation of
speciﬁc mRNAs and/or target those mRNAs for destruction by
sequence-speciﬁc cleavage and degradation [41]. Nevertheless, the
potential role of RNAi molecules as therapeutic molecules has been
limited due to issues relating to cellular uptake, long-term stability
and speciﬁcity of in vivo delivery into target tissue [20]. Recently,
Kadota et al. [25] have reported that the combined treatment with
the adenoviral vector expressing shRNA targeting TS and 5-FU-
derived agent S-1 showed a potent antitumor activity against 5-FU-
resistant tumor xenografts upon the intratumor injection of the
adenoviral vector. Besides the immunological problems and the
limitations in the size of the carried therapeutic gene encountered
with the use of viral vectors [42], systemic administration of
adenoviral vector expressing shRNA targeting TS failed to exert any
therapeutic beneﬁt against 5-FU-resistant tumor xenografts prob-
ably through the inefﬁecient in vivo delivery of genetic material tosing and thymidylate synthase silencing have synergistic antitumor
tp://dx.doi.org/10.1016/j.canlet.2016.11.005
Fig. 3. Antitumor efﬁcacy of combined treatment of PEG-coated shTS lipoplex and S-1 in human colorectal DLD-1 xenograft model. On days 5, 7, 9, 11, 13 and 15 post tumor
inoculation, PEG-coated shTS lipoplex (80 mg shRNA/mouse per injection) was intravenously injected into mice bearing DLD-1 tumors. Metronomic S-1 dosing (tegafur 6.9 mg/kg)
was orally administered daily from day 5e19 post tumor inoculation. For the control group, 9% sucrose solution was administered instead of S-1 or PEG-coated shTS lipoplex. (A)
Antitumor activity as assessed by determining the tumor size. Data represents the average of tumor volume in each group (n ¼ 6) ± S.D. *p < 0.05 versus PEG-coated shTS lipoplex-
or S-1-traeted group, ***p < 0.001 versus control. (B) A photograph of DLD-1 xenograft tumors taken 48 h after the end of treatment. A representative mouse per treatment group
shows signiﬁcant reduction of the tumor sizes that received a combined treatment of shTS and S-1 compared to single treatment with either shTS or S-1 alone. (C) Body weight
change during the therapeutic experiments.
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Fig. 4. Apoptosis in the tumor tissue induced by the combined treatment of PEG-coated shTS lipoplex and S-1. Mice bearing DLD-1 tumors were treated in the same way as
described in legend of Fig. 3. At 48 h post the last treatment, mice were euthanized, and tumors were excised, snap frozen, and examined for apoptosis. (A) Representative
immunoﬂuorescent tumor sections (TUNEL: Red, Hoechst 33342: Blue). The bar indicates 100 mm. Original magniﬁcation, 200. (B) Percent of TUNEL-positive cells in the section.
Data represent the mean ± S.D. *p < 0.05.
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conferred the speciﬁcity against the designated (TS) gene, indicated
by the potent gene silencing effect (Fig. 1), while minimizing the
off-target effect as indicated by the absence of remarkable toxicity
or the loss of body weight during treatment (Fig. 3C). Furthermore,
the non viral vector used, PEG-coated cationic liposome, was efﬁ-
cient in delivering the chemically synthesized shRNA to the tumor
tissue following systemic administration as ascribed by the potent
antitumor efﬁcacy (Fig. 3A and B) and the remarkable apoptotic
potential (Fig. 4A and B) induced by the combined traetment of S-1
and shTS-lipoplex. These lead an assumption that the combined
treatment of shTS-lipoplex with S-1 has effective antitumor activity
against 5-FU-resistant colorectal tumors. Further investigations are
in progress to verify the assumption in our laboratory.
Tumor priming with metronomic chemotherapy have been re-
ported to enhance the intratumor delivery and distribution of drugs
and/or macromolecules including drug delivery nanocarriers. Chen
and co-workers [43] have recently reported that tumor priming
with metronomic paclitaxel could induce tumor vasculature
normalization, as evidenced by the increased coverage of the per-
icytes and basement membranes of endothelial cells, by the
enhancement of pO2 and vascular perfusion, and by decreases in
the interstitial ﬂuid pressure. Such tumor vasculature normaliza-
tion efﬁciently enhanced systemic delivery and the resultant anti-
cancer efﬁcacy of a conventional chemotherapeutic agent,
doxorubicin, administered during the induced normalization win-
dow. More recently, we have veriﬁed that tumor priming with
metronomic S-1 dosing could induce a potent apoptotic response
against both tumor endothelial cells and tumor cells adjacent to
tumor angiogenic vessels as well, resulting in enhanced blood ﬂow
via transient normalization of tumor vasculature in tandem with
alleviating the mechanical compression exerted on tumor blood
vessels. Such alteration in the tumor microenvironment imparted
by metronomic S-1 dosing was acknowledged for the enhanced
intratumor delivery of PEGylated nanocarrier systems following
their systemic administration [44]. Therefore, based on these
recent studies, it is legitimate to account the superior antitumor
effect of the combined treatment of shTS lipoplex and S-1 dosing to
the metronomic S-1-mediated tumor priming effect which ensures
the efﬁcient in vivo delivery of PEG-coated shRNA lipoplexes to
tumor tissue. Such enhanced intratumor delivery and/or accumu-
lation of PEG-coated shTS lipoplexes is conﬁrmed to sensitize the
tumor cells to the cytotoxic effect of 5-FU derived from S-1 (Figs. 2
and 3) via down-regulating the expression of TS gene (Fig. 1), and
consequently, resulted in an enhanced antitumor efﬁcacy, as
manifested by the signiﬁcant reduction in tumor growth (Fig. 3)
and the potent induction of apoptosis within tumor tissues (Fig. 4).
Conclusion
The present study demoestrated that RNAi targeted speciﬁcally
against TS resulted in gene silencing with high efﬁcacy in human
DLD-1 colorectal cancer cells, leading to the inhibition of cell pro-
liferation in vitro and in vivo, when combined with 5-FU and 5-FU
prodrug S-1. Our results suggest that TS silencing may be a prom-
ising strategy to enhance the chemosensitivity of human CRC cells
to 5-FU-based chemotherapeutic regimens and the combinated
treament using shTS and metronomic S-1 dosing may constitute an
effective therapeutic option for advanced human CRC.
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